Using fluorescence imaging to improve surgery for esophageal and gastric cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the use of Indocyanine Green (ICG) and near infra-red (NIR) fluorescence imaging to enhance the surgical outcomes for patients undergoing esophagectomy or gastrectomy due to cancer. The focus is on increasing the number of lymph nodes resected and improving the quality of gastrointestinal tract anastomoses, which are critical for patient survival and recovery. By employing advanced imaging techniques, the study aims to provide surgeons with better guidance during operations, potentially leading to improved prognostic outcomes for patients. The study will include patients with resectable esophageal or gastric cancer who meet specific eligibility criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Man or woman over 18 years old.
* Patient with resectable primitive esophageal or gastric cancer confirmed by biopsy without distant metastases
* Patient with no contraindications to anaesthesia and performance of esophageal and/or gastric surgery
* Patient able to receive and understand information related to the study and give written informed consent.
* Patient affiliated to the French social security system.

Exclusion Criteria:

* Patient undergoing emergency surgery (hemorrhage, occlusion or perforation).
* Presence of distant metastasis
* Patient at risk of allergy to indocyanine green or to other fluorescent compounds
* Pregnant or lactating patient.
* Patient in exclusion period (determined by a previous or a current study).
* Patient under the protection of justice.
* Patient under guardianship or trusteeship.
* Patient deprived of liberty

Where it's running

• Service de Chirurgie Digestive et Endocrinienne, NHC
  Strasbourg, France Recruiting

Study contacts

• Principal investigator: Silvana PERRETTA, MD, PhD — Service de Chirurgie Digestive et Endocrinienne, NHC, Strasbourg
• Study coordinator: Armelle TAKEDA, PhD
• Email: armelle.takeda@ihu-strasbourg.eu
• Phone: +33 390413608

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors

  This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.

  Recruiting at 3 sites Phase 1 Sutro Biopharma, Inc. · Orlando, Florida and 5 other locations · NCT07807345

• Prehabilitation before high-risk cancer surgery

  This trial tests a multidisciplinary prehabilitation program to see if it helps adults with cancer recover better after major abdominal surgery.

  Recruiting Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07638410

• Molecular comparison of primary gastroesophageal cancers and their brain metastases

  This project will test whether key biomarkers (HER2, MSI, PD-L1, CLDN18.2) match between primary gastroesophageal tumors and their matched brain metastases using archived tissue.

  Recruiting Blokhin's Russian Cancer Research Center · Moscow · NCT07464470

• Sonesitatug vedotin plus capecitabine, with or without rilvegostomig, for CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma

  This trial will test whether adding sonesitatug vedotin to capecitabine, with or without rilvegostomig, helps people with untreated CLDN18.2-positive, HER2-negative advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma.

  Recruiting at 158 sites Phase 3 AstraZeneca · Birmingham, Alabama and 313 other locations · NCT07431281

• PET imaging that targets CLDN18.2 to find stomach, pancreatic, bile-duct, and esophageal cancers

  This project will try a CLDN18.2-targeted PET scan in adults with suspected or confirmed gastric, pancreatic, bile-duct, or esophageal cancer (and some healthy volunteers) to see if it can show CLDN18.2-positive tumors.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07301814

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.